| 2026 |
| 04/28 | 181 | 184 | 177 | 184 | +2.22% | 136,900 | 67億9585万 | -2.65% |
| 04/27 | 183 | 184 | 180 | 180 | -2.17% | 201,100 | 66億4812万 | -4.76% |
| 04/24 | 183 | 186 | 180 | 184 | -0.54% | 180,400 | 67億9585万 | -2.13% |
| 04/23 | 187 | 190 | 182 | 185 | -2.12% | 296,500 | 68億3279万 | -1.6% |
| 04/22 | 192 | 192 | 187 | 189 | -1.05% | 222,200 | 69億8052万 | 0% |
| 04/21 | 194 | 195 | 188 | 191 | -1.04% | 240,900 | 70億5439万 | +1.06% |
| 04/20 | 197 | 198 | 192 | 193 | -0.52% | 334,500 | 71億2826万 | +2.12% |
| 04/17 | 196 | 196 | 189 | 194 | -0.51% | 317,800 | 71億6519万 | +2.11% |
| 04/16 | 195 | 201 | 195 | 195 | 0% | 322,200 | 72億213万 | +2.63% |
| 04/15 | 16:00 2026年9月期 第2四半期(中間期)決算説明会のお知らせ |
| 04/15 | 191 | 196 | 190 | 195 | +1.56% | 324,100 | 72億213万 | +2.63% |
| 04/14 | 194 | 196 | 191 | 192 | 0% | 350,700 | 70億9132万 | +0.52% |
| 04/13 | 187 | 193 | 186 | 192 | +2.67% | 554,800 | 70億9132万 | +0.52% |
| 04/10 | 192 | 204 | 186 | 187 | -2.6% | 1,078,500 | 69億665万 | -2.09% |
| 04/09 | 202 | 202 | 186 | 192 | -4% | 1,096,200 | 70億9132万 | +0.52% |
| 04/08 | 191 | 204 | 190 | 200 | +5.82% | 4,320,700 | 73億8680万 | +5.26% |
| 04/07 | 197 | 198 | 183 | 189 | -2.07% | 1,724,000 | 69億8052万 | -0.53% |
| 04/06 | 16:00 PRISM BioLabとエーザイが共同創出したE7386、エーザイが米国がん学会(AACR)年次総会にて非臨床研究結果を発表 |
| 04/06 | 184 | 193 | 184 | 193 | +3.21% | 159,500 | 71億2826万 | +1.05% |
| 04/03 | 190 | 192 | 183 | 187 | -1.06% | 247,700 | 69億665万 | -2.6% |
| 04/02 | 189 | 197 | 188 | 189 | +0.53% | 392,800 | 69億8052万 | -2.07% |
| 04/01 | 182 | 189 | 182 | 188 | +5.03% | 237,200 | 69億4359万 | -2.59% |
| 03/31 | 184 | 184 | 178 | 179 | -1.1% | 303,800 | 66億1118万 | -7.73% |
| 03/30 | 182 | 186 | 180 | 181 | -5.73% | 311,900 | 66億8505万 | -7.18% |
| 03/27 | 180 | 193 | 180 | 192 | +6.08% | 336,100 | 70億9132万 | -2.04% |
| 03/26 | 193 | 193 | 179 | 181 | -7.18% | 532,500 | 66億8505万 | -8.59% |
| 03/25 | 182 | 197 | 180 | 195 | +13.37% | 1,349,600 | 72億213万 | -2.01% |
| 03/24 | 174 | 178 | 169 | 172 | +1.78% | 375,400 | 63億5264万 | -14% |
| 03/23 | 171 | 173 | 166 | 169 | -6.63% | 746,900 | 62億4184万 | -15.92% |
| 03/19 | 194 | 194 | 180 | 181 | -8.59% | 783,400 | 66億8505万 | -10.4% |
| 03/18 | 198 | 202 | 192 | 198 | +1.02% | 459,200 | 73億1293万 | -1.98% |
| 03/17 | 200 | 208 | 193 | 196 | -1.01% | 718,800 | 72億3906万 | -2.97% |
| 03/16 | 217 | 217 | 195 | 198 | -7.91% | 1,898,000 | 73億1293万 | -1.49% |
| 03/13 | 243 | 243 | 215 | 215 | +11.4% | 8,814,700 | 79億4081万 | +6.97% |
| 03/12 | 16:00 Receptor.AI Inc.との創薬提携契約締結のお知らせ |
| 03/12 | 203 | 203 | 192 | 193 | -5.39% | 206,800 | 71億2826万 | -3.5% |
| 03/11 | 205 | 211 | 202 | 204 | -0.97% | 251,800 | 75億3453万 | +2% |
| 03/10 | 190 | 213 | 189 | 206 | +10.16% | 865,300 | 76億840万 | +3.52% |
| 03/09 | 185 | 190 | 179 | 187 | -3.11% | 318,000 | 69億665万 | -6.03% |
| 03/06 | 186 | 197 | 186 | 193 | +1.05% | 292,800 | 71億2826万 | -3.02% |
| 03/05 | 189 | 197 | 186 | 191 | +5.52% | 432,500 | 70億5439万 | -3.54% |
| 03/04 | 190 | 197 | 178 | 181 | -10.4% | 967,500 | 66億8505万 | -8.12% |
| 03/03 | 209 | 214 | 202 | 202 | -2.42% | 413,900 | 74億6066万 | +2.54% |
| 03/02 | 213 | 215 | 203 | 207 | -5.91% | 484,800 | 76億4533万 | +5.08% |
| 02/27 | 195 | 221 | 195 | 220 | +12.82% | 1,043,700 | 81億2548万 | +12.24% |
| 02/26 | 197 | 201 | 193 | 195 | -1.02% | 319,400 | 72億213万 | 0% |
| 02/25 | 203 | 206 | 193 | 197 | -3.9% | 394,900 | 72億7599万 | +1.03% |
| 02/24 | 202 | 208 | 192 | 205 | +0.49% | 353,800 | 75億7147万 | +5.13% |
| 02/20 | 229 | 229 | 198 | 204 | -7.69% | 1,017,700 | 75億3453万 | +5.15% |
| 02/19 | 227 | 232 | 219 | 221 | -3.49% | 342,800 | 81億6241万 | +14.51% |
| 02/18 | 218 | 239 | 216 | 229 | +7.01% | 1,474,400 | 84億5788万 | +19.9% |
| 02/17 | 217 | 221 | 208 | 214 | -0.93% | 922,600 | 79億387万 | +13.23% |
| 02/16 | 184 | 217 | 183 | 216 | +12.5% | 1,434,900 | 79億7774万 | +14.89% |
| 02/13 | 16:30 営業外収益及び特別損失の計上に関するお知らせ |
| 02/13 | 16:30 2026年9月期第1四半期決算短信〔日本基準〕(非連結) |
| 02/13 | 200 | 200 | 192 | 192 | -3.52% | 391,600 | 70億9132万 | +3.23% |
| 02/12 | 194 | 203 | 193 | 199 | +2.58% | 524,600 | 73億4986万 | +7.57% |
| 02/10 | 187 | 196 | 187 | 194 | +4.3% | 256,900 | 71億6519万 | +5.43% |
| 02/09 | 187 | 187 | 181 | 186 | 0% | 222,200 | 68億6972万 | +2.2% |
| 02/06 | 187 | 189 | 183 | 186 | -3.13% | 337,300 | 68億6972万 | +2.76% |
| 02/05 | 190 | 197 | 190 | 192 | +0.52% | 195,800 | 70億9132万 | +6.67% |
| 02/04 | 192 | 192 | 188 | 191 | 0% | 173,100 | 70億5439万 | +7.3% |
| 02/03 | 186 | 194 | 185 | 191 | +3.24% | 357,300 | 70億5439万 | +7.91% |
| 02/02 | 189 | 192 | 184 | 185 | -3.14% | 198,500 | 68億3279万 | +5.71% |
| 01/30 | 185 | 192 | 184 | 191 | +3.8% | 412,800 | 70億5439万 | +9.77% |
| 01/29 | 179 | 189 | 174 | 184 | +5.75% | 406,400 | 67億9585万 | +6.36% |
| 01/28 | 178 | 179 | 172 | 174 | -3.87% | 390,400 | 64億2651万 | +1.16% |
| 01/27 | 180 | 182 | 178 | 181 | 0% | 127,500 | 66億8505万 | +5.23% |
| 01/26 | 186 | 188 | 181 | 181 | -4.74% | 272,300 | 66億8505万 | +5.85% |
| 01/23 | 186 | 194 | 182 | 190 | +3.26% | 311,000 | 70億1746万 | +12.43% |
| 01/22 | 194 | 195 | 181 | 184 | -3.66% | 535,500 | 67億9585万 | +10.18% |
| 01/21 | 16:00 PRISM BioLabとエーザイが共同創出したE7386、ESMO OPEN 誌にて第I相臨床試験結果に関する学術論文が発表される |
| 01/21 | 197 | 197 | 187 | 191 | -3.54% | 335,000 | 70億5095万 | +15.06% |
| 01/20 | 193 | 198 | 186 | 198 | -1.49% | 704,500 | 73億936万 | +20% |
| 01/19 | 195 | 207 | 189 | 201 | +8.65% | 1,192,000 | 74億2011万 | +23.31% |
| 01/16 | 189 | 191 | 180 | 185 | +3.35% | 685,500 | 68億2946万 | +14.2% |
| 01/15 | 168 | 181 | 166 | 179 | +5.92% | 462,300 | 66億796万 | +10.49% |
| 01/14 | 171 | 176 | 167 | 169 | -1.74% | 400,000 | 62億3880万 | +4.32% |
| 01/13 | 178 | 179 | 170 | 172 | -3.37% | 361,700 | 63億4955万 | +6.17% |
| 01/09 | 179 | 185 | 176 | 178 | -1.11% | 374,400 | 65億7104万 | +9.2% |
| 01/08 | 169 | 182 | 167 | 180 | +7.78% | 886,800 | 66億4488万 | +10.43% |
| 01/07 | 161 | 169 | 160 | 167 | +5.7% | 349,500 | 61億6497万 | +1.21% |
| 01/06 | 160 | 162 | 157 | 158 | -1.86% | 246,100 | 58億3272万 | -4.82% |
| 01/05 | 156 | 163 | 156 | 161 | +3.21% | 201,000 | 59億4347万 | -3.01% |
| 2025 |
| 12/30 | 159 | 162 | 156 | 156 | -3.11% | 240,200 | 57億5889万 | -6.59% |
| 12/29 | 158 | 168 | 156 | 161 | +5.23% | 681,800 | 59億4347万 | -4.17% |
| 12/26 | 154 | 159 | 153 | 153 | -0.65% | 473,600 | 56億4814万 | -8.93% |
| 12/25 | 150 | 154 | 149 | 154 | +4.05% | 463,700 | 56億8506万 | -8.88% |
| 12/24 | 15:30 事業計画及び成長可能性に関する説明資料 |
| 12/24 | 153 | 154 | 148 | 148 | -3.27% | 535,300 | 54億6356万 | -12.43% |
| 12/23 | 160 | 161 | 150 | 153 | -1.29% | 636,600 | 56億4814万 | -11.05% |
| 12/22 | 162 | 165 | 154 | 155 | -7.19% | 1,113,200 | 57億1795万 | -10.4% |
| 12/19 | 202 | 203 | 163 | 167 | -10.7% | 7,198,600 | 61億6063万 | -3.47% |
| 12/18 | 187 | 187 | 187 | 187 | +36.5% | 89,700 | 68億9843万 | +8.72% |
| 12/17 | 16:00 Talus Bioscience, Inc.との共同研究契約締結のお知らせ |
| 12/17 | 16:00 PRISM BioLab とエーザイが共同創出したE7386、Clinical Cancer Research誌にて非臨床研究結果に関する学術論文が発表される |
| 12/17 | 143 | 144 | 136 | 137 | -3.52% | 575,500 | 50億5393万 | -19.88% |
| 12/16 | 151 | 152 | 142 | 142 | -4.7% | 747,500 | 52億3838万 | -16.96% |
| 12/15 | 152 | 154 | 148 | 149 | -2.61% | 587,100 | 54億9661万 | -12.87% |
| 12/12 | 156 | 157 | 153 | 153 | 0% | 264,100 | 56億4417万 | -10.53% |
| 12/11 | 159 | 161 | 152 | 153 | -3.77% | 553,100 | 56億4417万 | -10.53% |
| 12/10 | 170 | 171 | 153 | 159 | -5.92% | 1,689,600 | 58億6551万 | -6.47% |
| 12/09 | 179 | 182 | 168 | 169 | -9.14% | 1,397,300 | 62億3441万 | 0% |
| 12/08 | 171 | 195 | 171 | 186 | +5.08% | 2,466,800 | 68億6154万 | +10.71% |
| 12/05 | 176 | 180 | 166 | 177 | -1.12% | 1,395,500 | 65億2953万 | +5.99% |
| 12/04 | 180 | 189 | 178 | 179 | -2.72% | 1,339,600 | 66億331万 | +7.83% |
| 12/03 | 189 | 200 | 176 | 184 | -6.12% | 3,949,400 | 67億8776万 | +11.52% |
| 12/02 | 242 | 279 | 189 | 196 | -13.27% | 14,129,600 | 72億3044万 | +19.51% |
| 12/01 | 190 | 230 | 182 | 226 | +25.56% | 11,520,700 | 83億3714万 | +38.65% |
| 11/28 | 16:30 PRISM BioLab、PepMetics化合物の新規二環性化合物の特許取得のお知らせ |
| 11/26 | 8:00 2025年9月期 決算説明会 ログミーFinance書き起こし記事公開のお知らせ |